<DOC>
	<DOCNO>NCT00701285</DOCNO>
	<brief_summary>We want evaluate utility statin heart function accord potency . Patients chronic ischemic heart failure administer pitavastatin 4mg pravastatin 10mg 52 week . Then evaluate effect pitavastatin pravastatin primarily rate hospitalization cardiovascular cause lipid profile secondarily biomarker , echocardiography parameter , 6-minute walk , change NYHA class distribution , cardiovascular mortality .</brief_summary>
	<brief_title>South Korean Pitavastatin Heart Failure Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>1 . Patients accept enter study write informed consent 2 . Age ≥ 30 year 3 . LDLcholesterol ≥ 70mg/dl 4 . Chronic heart failure : NYHA class II ~ III Ischemic etiology Left ventricular ejection fraction &lt; 45 % Optimal therapy chronic heart failure stable clinical condition two week . 1 . Patients participate study 3 month enrollment 2 . Statin treatment within 2 month enrollment 3 . Unstable decompensated heart failure enrollment 4 . Acute coronary syndrome cerebral vascular disease within 3 month enrollment 5 . Coronary revascularization within 3 month enrollment plan enrollment 6 . Any serious disease condition might effect life expectancy malignancy , lifethreatening infectious disease . 7 . Serum creatinine level &gt; = 3.0 mg/dl 8 . AST AST level &gt; =2.5 time ULN 9 . CK level &gt; =2 time ULN 10 . Uncontrolled hypothyroidism : TSH level &gt; = 2 time ULN 11 . Pregnant breastfeed woman , woman want bear 12 . Patients might unsuitable decision investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>heart failure</keyword>
	<keyword>pitavastatin</keyword>
	<keyword>pravastatin</keyword>
	<keyword>statin</keyword>
</DOC>